Posts

Efficacy of combined therapy with fish oil and phytocannabinoids in murine intestinal inflammation

Authors: Ester Pagano, Fabio A. Iannotti, Fabiana Piscitelli, Barbara Romano, Giuseppe Lucariello, Tommaso Venneri, Vincenzo Di Marzo, Angelo A. Izzo, Francesca Borrelli Published in Phytotherapy Research September 2020 Abstract Summary Fish oil (FO) and phytocannabinoids have received considerable attention for their intestinal anti‐inflammatory effects. We investigated whether the combination of FO with cannabigerol (CBG) and…

Activation of Cannabinoid Receptor 2 Prevents Colitis-Associated Colon Cancer through Myeloid Cell De-activation Upstream of IL-22 Production

Authors: William Becker, Haider Rasheed Alrafa,Kiesha Wilson, Kathryn Miranda, Courtney Culpepper, Ioulia Chatzistamou, Guoshuai Cai, Mitzi Nagarkatti, Prakash S. Nagarkatti Published in Iscience August 2020 Abstract Summary Intestinal disequilibrium leads to inflammatory bowel disease (IBD), and chronic inflammation predisposes to oncogenesis. Antigen-presenting dendritic cells (DCs) and macrophages can tip the equilibrium toward tolerance or pathology….

Role of cannabis in inflammatory bowel diseases.

Authors: Abhilash Perisetti, Afrina Hossain Rimu, Salman Ali Khan, Pardeep Bansal, Hemant Goyal
Annals of Gastroenterology, March-April 2020

For many centuries, cannabis (marijuana) has been used for both recreational and medicinal purposes. Currently, there are about 192 million cannabis users worldwide, constituting approximately 3.9% of the global population. Cannabis comprises more than 70 aromatic hydrocarbon …

The Endocannabinoid System in Pediatric Inflammatory and Immune Diseases.

Authors: Maura Argenziano, Chiara Tortora, Giulia Bellini, Alessandra Di Paola, Francesca Punzo, et al
International Journal of Molecular Sciences, 23 November 2019

Endocannabinoid system consists of cannabinoid type 1 (CB1) and cannabinoid type 2 (CB2) receptors, their endogenous ligands, and the enzymes responsible for their synthesis and degradation. CB2, to a great extent, and CB1, to a lesser extent, are involved in regulating the im…

Association between cannabis use and complications related to ulcerative colitis in hospitalized patients: A propensity matched retrospective cohort study.

Authors: Chimezie Mbachi, Bashar Attar, Olamide Oyenubi, Wang Yuchen, Aisien Efesomwan, et al
Medicine, August 2019

Ulcerative colitis (UC) is a chronic inflammatory process that is occasionally associated with complications that cause significant morbidity and mortality. Studies in experimental animal models have demonstrated a beneficial effect of cannabis on intestinal inflammation. It i…

Intestinal permeability–a new target for disease prevention and therapy.

Authors: Stephan C. Bischoff, Giovanni Barbara, Wim Buurman, Theo Ockhuizen, Jörg-Dieter Schulzke, et al
BMC Gastroenterology, 18 November 2014

Data are accumulating that emphasize the important role of the intestinal barrier and intestinal permeability for health and disease. However, these terms are poorly defined, their assessment is a matter of debate, and their clinical significance is not clearly established. In…

Cannabis finds its way into treatment of Crohn’s disease.

Authors: Rudolf Schicho, Martin Storr
Pharmacology, 2014

In ancient medicine, cannabis has been widely used to cure disturbances and inflammation of the bowel. A recent clinical study now shows that the medicinal plant Cannabis sativa has lived up to expectations and proved to be highly efficient in cases of inflammatory bowel disea…

Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study.

Authors: Timna Naftali, Timna Naftali, Lihi Bar-Lev Schleider, Iris Dotan, Ephraim Philip Lansky, et al
Clinical Gastroenterology and Hepatology, October 2013

BACKGROUND & AIMS: The marijuana plant Cannabis sativa has been reported to produce beneficial effects for patients with inflammatory bowel diseases, but this has not been investigated in controlled trials. We performed a prospective trial to determine whether cannabis can ind…

Cannabis use amongst patients with inflammatory bowel disease.

Authors: Simon Lal, Neeraj Prasad, Manijeh Ryan, Sabrena Tangri, Mark Silverberg, et al
European Journal of Gastroenterology & Hepatology, October 2011

BACKGROUND: Experimental evidence suggests the endogenous cannabinoid system may protect against colonic inflammation, leading to the possibility that activation of this system may have a therapeutic role in inflammatory bowel disease (IBD). Medicinal use of cannabis for chron…

Treatment of Crohn’s disease with cannabis: an observational study.

Authors: T. Naftali, L. Bar Lev, D. Yablekovitz, E. Half, F.M. Konikoff
Israel Medical Association Journal, August 2011

BACKGROUND: The marijuana plant cannabis is known to have therapeutic effects, including improvement of inflammatory processes. However, no report of patients using cannabis for Crohn’s disease (CD) was ever published. OBJECTIVES: To describe the effects of cannabis use in pat…

Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis.

Authors: Francesca Borrelli, Gabriella Aviello, Barbara Romano, Pierangelo Orlando, et al
Journal of Molecular Medicine, November 2009

Inflammatory bowel disease affects millions of individuals; nevertheless, pharmacological treatment is disappointingly unsatisfactory. Cannabidiol, a safe and non-psychotropic ingredient of marijuana, exerts pharmacological effects (e.g., antioxidant) and mechanisms (e.g., inh…